{'fraction_non_alphanumeric': 0.050505050505050504, 'fraction_numerical': 0.047619047619047616, 'mean_word_length': 5.034782608695652, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Intra‐lesional interleukin‐2 therapy for in transit melanoma

Intra‐lesional interleukin‐2 (IL‐2) is effective in treating in transit melanoma metastases. Results from multiple studies were examined to evaluate the efficacy of IL‐2 for in transit disease. In the published literature, complete response ranged from 0% to 69% per patient, and 41% to 96% per lesion, with excellent tolerability. Combining the results of six studies show complete response in 50% of patients and 78% of lesions. Intra‐lesional IL‐2 should be considered early in the course of treatment for in transit disease, ahead of other, more toxic therapies. J. Surg. Oncol. 2014 109:327–331. © 2014 Wiley Periodicals, Inc.